Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Giuseppe Esposito

Nuclear Medicine Washington, DC Medical Doctor

NPI 1114918141 CMS profile 452112

3800 Reservoir Rd Nw, 2005 Gorman, Washington, DC 20007

Open in the dashboard

General payments

$414,114

292 records reported · program years 2019–2025

Research payments

$104,637

Paid to them · 20 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$924,862 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Giuseppe Esposito of Washington, DC is reported in the CMS Open Payments database as having received $414,114 across 292 general payments and $104,637 in research payments paid to them. Separately, studies naming them as principal investigator received $924,862 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Nuclear Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

13 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $29,248 32
2025 Research $38,750 1
2024 General $119,187 92
2024 Research $16,000 1
2023 General $74,282 64
2023 Research $11,125 2
2022 General $37,586 39
2021 General $110,985 15
2021 Research $1,313 3
2020 General $11,917 22
2020 Research $3,325 6
2019 General $30,909 28
2019 Research $34,125 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Giuseppe Esposito
  • Nuclear Medicine median
  • Middle half of Nuclear Medicine
  • National median

In program year 2025, general payments to Giuseppe Esposito were reported at $29,248. Among 197 Nuclear Medicine profiles paid that year, the median was $146 and the middle half received between $40 and $372.

Show as a table
Year Giuseppe Esposito Nuclear Medicine median Middle half National median
2019 $30,909 $125 $54–$531 $163
2020 $11,917 $99 $34–$2,125 $114
2021 $110,985 $96 $22–$874 $132
2022 $37,586 $102 $38–$240 $149
2023 $74,282 $123 $51–$257 $160
2024 $119,187 $121 $51–$390 $164
2025 $29,248 $146 $40–$372 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Progenics Pharmaceuticals, Inc. $231,833 183 payments
  2. Blue Earth Diagnostics Limited $126,227 25 payments
  3. Advanced Accelerator Applications $34,834 42 payments
  4. Ge Healthcare $7,729 22 payments
  5. Eisai Inc. $6,517 2 payments
  6. Piramal Imaging Limited $1,900 5 payments
  7. Eli Lilly and Company $1,725 1 payment
  8. Avid Radiopharmaceuticals, Inc. $1,249 3 payments
  9. Incyte Corporation $987 3 payments
  10. Telix Pharmaceuticals $931 2 payments
  11. Other $183 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $220,041 58 payments
  2. Consulting Fee $148,647 37 payments
  3. Travel and Lodging $38,291 99 payments
  4. Food and Beverage $7,135 98 payments
Products named General payments · program years 2019–2025
  1. PYLARIFY $229,358 180 payments
  2. Lutathera Radioactive targeted therapy - Neuroendocrine tumors $24,868 23 payments
  3. Axumin Diagnostic Imaging $7,792 5 payments
  4. Vizamyl $5,000 2 payments
  5. LUTATHERA Oncology $4,969 17 payments
  6. POSLUMA $1,973 2 payments
  7. NEURACEQ $1,900 5 payments
  8. Axumin Diagnostic Imaging $900 1 payment
  9. ILLUCCIX $893 1 payment
  10. TheraSphere Y90 Glass Microspheres 10 GBq $20 1 payment
  11. Other $20 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Avid Radiopharmaceuticals, Inc. $54,750 2 payments
  2. Regeneron Pharmaceuticals, Inc. $30,637 16 payments
  3. Progenics Pharmaceuticals, Inc. $19,250 2 payments

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$57,685

Medicare's payments for the services billed

Medicare patients

802

Average age 75

Services billed

935

411 women, 391 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Cancer 47%
Ischemic heart disease 42%
Diabetes 40%
Chronic kidney disease 38%
Depression 29%
Heart failure 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
PYLARIFY
  • Progenics Pharmaceuticals, Inc. $108,297
$108,297 — —
POSLUMA
  • Blue Earth Diagnostics Limited $1,950
$1,950 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

312 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nuclear Medicine in District of Columbia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record